COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic.
This Guidelines summary is based on guidance included within the Children’s Liver Disease Foundation Yellow Alert Pack, written to provide general guidelines on the early identification of liver disease in infants and their referral where appropriate.
This summary covers the key points for GPs to consider when interpreting results from liver blood tests and how to respond to detected abnormalities.
A summary of NICE guidance on non-alcoholic fatty liver disease. Includes identification, lifestyle advice, and pharmacological treatment.
This webinar has been initiated and commissioned by Intercept Pharma UK and Ireland Ltd and organised in partnership with Guidelines. Intercept Pharma UK and Ireland Ltd has reviewed the scope of the webinar, commissioned the speakers, and approved all materials related to the webinar. The speakers have been paid an ...